A subset of head and neck cancers is associated with the human papillomavirus (HPV). Viral infection is closely correlated with expression of p16 INK4A in these tumors. We evaluated p16
INTRODUCTION
Although tobacco and alcohol consumption are the primary risk factors for development of head and neck squamous cell carcinoma (HNSCC), it has recently become evident that infection with high-risk human papillomavirus (HPV) is etiologically linked to a subgroup of cancers in the head and neck region. [1] [2] [3] Some 90% of HPV-positive head and neck tumors are infected with high-risk HPV16. 4, 5 Viral DNA is detected in some 20% of HNSCCs, the strongest association being found in oropharyngeal tumors, where carcinomas of the tonsils are particularly associated with HPV infection. [4] [5] [6] [7] Recent studies have indicated that in HNSCC, patients with HPV-infected tumors have a more favorable prognosis compared with patients whose tumors are virus-negative.
8-11 HPV positivity seems to be associated with lower exposure to tobacco and alcohol and with younger age at time of diagnosis, factors that may by themselves positively influence prognosis regardless of tumor biology. However, evidence is accumulating that HPV-positive tumors represent a separate biologic subgroup of HNSCC distinct from those carcinomas that are induced by tobacco and alcohol. The biologic differences between these subtypes of HNSCC may per se have an impact on prognosis. 1, 12 The viral oncogene products E6 and E7 play a key role in HPV-associated carcinogenesis, abrogating p53 and retinoblastoma (Rb) tumor suppressor functions, respectively.
13,14 HPV-positive HNSCCs are generally associated with wild-type TP53, as opposed to tobacco-induced tumors, which are characterized by genetic alterations of the TP53 pathway.
12, 13 The functional inactivation of Rb by E7 leads in turn to upregulation of the p16 INK4A represent those tumors in which HPV has been involved in the carcinogenic process.
18
Thus there is good evidence that p16
INK4A positivity may be regarded as a biomarker for tumors harboring clinically and oncogenetically relevant HPV infections.
HNSCC is predominantly a locoregional disease, and achieving local tumor control is essential for survival. 19 Radiotherapy can significantly improve local control and disease-specific survival in patients with HNSCC, either when used as a single treatment modality or in combination with chemotherapy 20 or hypoxic modification.
21,22
Over the years, radiotherapy has been optimized through modification of tumor hypoxia and by reducing overall treatment time of radiotherapy. [21] [22] [23] [24] Although this has resulted in improved treatment response for patients with HNSCC as a whole, individual patients with HNSCC still show considerable variation in clinical outcome. This indicates that other factors defining tumor response are still to be discovered, 25, 26 and HPV infection may be one such factor. With the present study, we aimed to evaluate the impact of HPV-associated tumor cell p16
INK4A expression on response to radiotherapy and survival in a well-characterized and prospectively collected cohort of Danish patients with head and neck cancer treated with conventionally fractionated radiotherapy alone.
PATIENTS AND METHODS

Patients and Tissues
One hundred ninety-five patients with primary squamous cell carcinoma of the pharynx (stages I through IV) or supraglottic larynx (stages II through IV) were enrolled in the placebo arm of the randomized Danish Head and Neck Cancer Group (DAHANCA) 5 protocol from January 1986 to September 1990. 22 Patients in this arm received primary conventionally fractionated radiotherapy (66 to 68 Gy in 33 to 34 fractions, 5 fractions/wk) as the only treatment. Routine paraffin-embedded, formalin-fixed pretreatment tumor tissues were available from the pathology archives in sufficient amounts for study in 156 of the total 195 patients (80%).The DAHANCA 5 study was designed according to the Helsinki Declaration II, and the patients gave written informed consent. Both the main study and the tumor tissue analyses were approved by the local ethics committees according to Danish law and regulations.
Evaluation of p16
INK4A Expression Immunohistochemistry for p16
INK4A expression was performed on a BenchMark XT autostainer (Ventana Medical Systems, Illkirch, France) according to the manufacturer's recommendations. Briefly, paraffin sections were cut at 5 m on Superfrost plus charged glass slides (Menzel-Glaser, Braunschweig, Germany), heated at 60°C for 1 hour, and deparaffinized in the instrument with EZ prep solution (Ventana Medical Systems). Heat-induced antigen retrieval was carried out using Cell Conditioning 1 solution (CC1, Ventana Medical Systems). p16
INK4A was detected by incubating sections with antibody clone JC8 (sc-56330; Santa Cruz Biotechnology Inc, Santa Cruz, CA) diluted 1:25 for 32 minutes. This is a mouse monoclonal immunoglobulin G2a antibody raised against full-length human p16, particularly suitable for use on formalin-fixed, paraffin-embedded sections. Its specificity has been confirmed by Western blotting. Specific reactions were detected using ultraView Universal DAB Detection Kit (Ventana Medical Systems), and the slides were counterstained with hematoxylin. Sections of p16
INK4A
-positive cervical carcinoma were used as positive controls. p16
INK4A expression was associated with distinct diffuse nuclear and cytoplasmic staining of epithelial cells. Tumors were classified dichotomously as either p16
-positive (strong, diffuse nuclear and cytoplasmic staining in Ͼ 10% of carcinoma cells) or negative (Fig 1) .
Detection of HPV Infection
To demonstrate the correlation between HPV16 infection and tumor cell expression of p16
INK4A
, we performed a pilot study on a separate series of 32 tonsillar carcinomas, using in situ hybridization for detection of viral DNA. Briefly, 5-m formalin-fixed, paraffin-embedded tumor sections were deparaffinized and treated with Dako Target Retrieval Solution (Dako, Glostrup, Denmark). Sections were digested with proteinase K (Dako, S3004) and rinsed in deionized water. Biotinylated HPV16-type specific DNA probe (Dako, code Y1407) in hybridization mixture was used according to the manufacturer's recommendations. Denaturation and hybridization were carried out using a Hybridizer Instrument (Dako). Sections were denatured for 5 minutes at 92°C and hybridized overnight at 37°C. After stringent washing, hybridized probe was detected using the tyramide-based GenPoint Catalyzed Signal Amplification System (Dako, code K0620), with consecutive application of primary peroxidase-conjugated streptavidin, biotinyl tyramide, and secondary peroxidase-conjugated streptavidin. Signals were visualized with the chromogen 3,3-diaminobenzidine. Positive and negative control sections (SiHa, HeLa, bladder cancer J82) were included. Carcinomas were classified as HPV16 positive when a discrete signal was seen localized to the nuclei of tumor cells. Signals were categorized as either punctuate and/or diffuse, representing integrated and episomal virus, respectively.
28-30
The findings of the pilot study have been previously published in abstract form. 31 We found a strong correlation between HPV16 DNA detection and p16
INK4A expression (Fig 1, Table 1 ).
Statistical Analysis
The end points used were locoregional control after radiotherapy, disease-specific survival, and overall survival. Locoregional control was defined as complete and persistent disappearance of the disease in the primary tumor (T site) and regional lymph nodes (N site) after radiotherapy. Failure was recorded in the event of recurrent tumor or if the primary tumor never completely disappeared. In the latter situation, the tumor was then assumed to have failed at the time of randomization. The end point does not, therefore, include the effect of a successful procedure with salvage surgery. Diseasespecific survival was defined as death from or with the actual cancer, and overall survival was defined as death from any cause. Follow-up of the patients was completed in connection with the original publication of the study. 22 All patients were observed for at least 5 years or until death. The survival status has subsequently been tracked until June 2004.
Features of p16
INK4A
-positive and -negative tumors were compared using the 2 test for categoric variables. The actuarial values of the end points were evaluated by the Kaplan-Meier analysis and compared using the log-rank test. A multivariate Cox proportional hazard analysis was used to evaluate prognostic parameters and treatment with respect to the risk of locoregional failure, disease-specific death, and overall death. Analyses were done with the STATA statistical package, version 9 (STATA Corp, College Station, TX). Comprehensive Meta-Analysis version 2.0 (Biostat, Englewood, NJ) was used to compose the Forest Plot. All results were considered significant at levels less than 5% (two-sided tests), and odds ratios (OR) are presented with 95% CIs.
RESULTS
Thirty-five (22%) of the 156 tumors expressed p16
INK4A
. -negative group (P ϭ .004). Median age and sex did not differ significantly between the groups, and the vast majority of patients in both groups were diagnosed in disease stage III or IV. Similarly, no statistically significant difference between the groups regarding histopathologic tumor differentiation was found.
At the time of evaluation, 97 patients had failed to achieve persistent locoregional control within the irradiated volume. A total of 93 patients had died with or from the cancer in question, and overall, 134 patients had died. The number of locoregional failures was associated with high stage of disease (stage III to IV; P ϭ .05) and, to a lesser extent, to nodal spread (P ϭ .08) and high tumor classification (T3/4; P ϭ .09). Patients with p16
-positive tumors were significantly less likely to suffer locoregional recurrence than were patients with p16 -negative tumors (58% v 28%, respectively; P ϭ .0005; OR, 0.26; 95% CI, 0.12 to 0.57). Looking in detail at locoregional tumor control after radiotherapy, tumor expression of p16
INK4A is seen to be associated with benefit in all subgroups; however, this benefit is greater in certain subgroups compared with others (Fig 3) . The more advanced the disease (Nϩ, stage III to IV), the greater the benefit. Patients with histopathologically poorly differentiated tumors or with tumors of oropharyngeal origin profit more from having tumor cell p16
INK4A positivity than do patients with moderately or well-differentiated tumors or with tumors of nonoropharyngeal origin. Moreover, women with p16 
DISCUSSION
We analyzed the association of tumor p16
INK4A expression with therapeutic response in a prospectively collected cohort of patients with HNSCC treated with radiotherapy alone. This study shows that tumor cell expression of p16 INK4A in this group of patients is associated with markedly improved treatment response and survival and that p16 INK4A expression status is an independent prognostic factor for both outcomes. The potent prognostic value of p16 INK4A expression is emphasized by the fact that this marker proved to be an even stronger independent prognostic factor than the classical clinical parameters of tumor stage and nodal status, the only other independent variables of prognostic significance in this study. The beneficial locoregional control rate observed in the p16 Analysis of known patient and tumor characteristics identified no substantial differences between the two patient groups. In particular, p16
INK4A
-positive tumors seemed to be more closely associated with poor histopathologic differentiation (54%) compared with p16
-negative tumors (38%), but the difference was not significant at the 5% level, possibly because of lack of power. The majority of patients in both groups had nodal spread at time of diagnosis (63% and 59%, respectively), which reflects that patients with HNSCC in general are diagnosed at advanced stages regardless of p16 INK4A status. However, patients with p16
-positive tumors could potentially have less comorbidity and a different risk profile in terms of exposure to tobacco and alcohol than the patients in the p16 INK4A -negative group. Information on lifetime exposure to tobacco and alcohol and performance status was, however, not available. Therefore, confounding by these variables on the survival analysis cannot be completely ruled out.
Recent studies have demonstrated the correlation between HPV and p16 INK4A expression status in HNSCC. 9,10,17,32 Using HPV16 DNA in situ hybridization and p16
INK4A immunohistochemistry on parallel sections in a series of tonsillar carcinomas, we confirmed these findings. We believe that p16
INK4A expression is a reliable biomarker of infection with HPV in HNSCC. However, the importance of p16
INK4A may potentially extend beyond that of merely being a surrogate marker of infection with HPV. From the molecular processes involved in viral carcinogenesis, it is possible to argue the case that p16
INK4A positivity may specifically identify HPV infections in HNSCC that are biologically relevant in carcinogenesis (ie, infections in those tumors in which HPV is transcriptionally active). A similar hypothesis was proposed and tested by Weinberger et al. 10 They demonstrated that double positivity in tumors for both HPV infection and 
